Go to the list of all blogs
Anna G's Avatar
published in Blogs
Sep 16, 2023
TickeronGET DAILY SIGNALS
📈Akoustis Technologies (AKTS): Volume Soars with +244% 5-Day Streak! What’s Behind the Surge?🚀

📈Akoustis Technologies (AKTS): Volume Soars with +244% 5-Day Streak! What’s Behind the Surge?🚀

🚀 Ready to Dive into AI-Powered Trading? Discover the Top 10 AI Robots! 📊

 if you're interested in AI trading and want to explore the top 10 AI robots, you can find them at the following links:

  1. Top 10 AI Robots  - SORT BY Sharper 
  2. Top 10 AI Robots  - SORT BY  30-day Annualized Return
  3. Top 10 AI Robots  - SORT BY  All Time Annualized Return

These AI robots are designed to provide insights and strategies to enhance your trading experience. Feel free to explore them and discover how AI can empower your trading decisions. 🤖📈

Akoustis Technologies

$AKTS has been making waves in the stock market lately, especially with its notable volume surge. Over the past five consecutive days, AKTS has seen an impressive average daily volume strong performance. Despite the broader Telecommunications Equipment industry trending downwards, this stock has drawn considerable attention from investors and traders alike.

📊Volume vs. Price Dynamics

The stock's volume momentum contrasts with its recent price performance. AKTS experienced a price decline of -39.05%, settling at $0.92. Such a divergence between volume and price could suggest a potential trend reversal, making it an enticing buy signal for some investors. Historical data seems to support this bullish view: A.I.dvisor's analysis of 48 similar volume-price patterns in the past found that 39 (or 81%) were followed by positive price movements.

🔢Earnings Report

However, it’s crucial to factor in the company’s recent earnings report from September 06. AKTS reported an earnings per share (EPS) of -20 cents, falling short of the estimated -16 cents. The firm’s current market capitalization stands at 75.25M, backed by 2.41M shares outstanding.

🌐Industry Overview

AKTS is nestled within the Telecommunications Equipment industry, which has been grappling with an average weekly price decline of -1%. This industry is responsible for producing a myriad of critical communications equipment, from fiber optic products to satellite systems. Titans in this space include Cisco Systems, Nokia Corp, and Apple Inc., amongst others.

💹Market Capitalization Insights

The Telecommunications Equipment Industry has a broad market cap spectrum, ranging from a meager 1.59K to a whopping 229.87B. Unsurprisingly, Cisco Systems (CSCO) claims the throne with the highest valuation, whereas ABILF stands at the other end of the spectrum.

📉Recent Performance

The last five trading days for AKTS weren't too rosy, with the stock shedding -16.34%. This was accompanied by a trade volume of approximately 285,696 shares daily. A significant drawdown of -36.05% was observed during this period.

While Akoustis Technologies has experienced a dip in its stock price, the explosive volume could hint at a turning point. As always, investors should conduct their due diligence and factor in both the micro and macroeconomic elements before making investment decisions.

Join us next week as we dive deeper into the intricacies of the Telecommunications Equipment industry and explore potential hidden gems!

Related Ticker: AKTS

AKTS's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for AKTS turned positive on October 21, 2026. Looking at past instances where AKTS's MACD turned positive, the stock continued to rise in 29 of 31 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for AKTS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

Following a +2.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKTS advanced for three days, in 173 of 207 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

AKTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 40 cases where AKTS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKTS as a result. In 58 of 65 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The 50-day moving average for AKTS moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for AKTS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.674) is normal, around the industry mean (3.104). P/E Ratio (-11.035) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. AKTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.19B. The market cap for tickers in the group ranges from 58 to 140.2B. VRTX holds the highest valuation in this group at 140.2B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -16%. INO experienced the highest price growth at 117%, while ABOS experienced the biggest fall at -89%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 28%. For the same stocks of the Industry, the average monthly volume growth was 53% and the average quarterly volume growth was -18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 66
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
AKTS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of filter products for radio frequency front-ends for mobile wireless devices

Industry Biotechnology

Industry
Telecommunications Equipment
Address
17 Drydock Avenue
Phone
+1 617 461-4023
Employees
75
Web
https://www.aktisoncology.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
Shares of DQ are declining approximately 14.00% on Wednesday, April 29, 2026, falling from a prior close of approximately $22.04 to approximately $18.96, as Q1 2026 financial results released before market open confirmed that the catastrophic polysilicon price environment decimating China's solar supply chain has deepened rather than stabilized in the first quarter of the year.
Shares of MX are declining approximately 31.00% on Wednesday, April 29, 2026, plunging from a prior close of $4.87 to approximately $3.36, in a sharp post-earnings selloff despite Q1 2026 results that technically came in ahead of depressed analyst estimates — confirming that the market's primary concern is forward profitability and the sustainability of the stock's extraordinary year-to-date rally rather than quarterly headline metrics.